MARKET

OCUP

OCUP

Ocuphire Pharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.890
-0.030
-0.61%
Opening 10:23 04/23 EDT
OPEN
5.07
PREV CLOSE
4.920
HIGH
5.07
LOW
4.760
VOLUME
75.34K
TURNOVER
--
52 WEEK HIGH
14.80
52 WEEK LOW
3.680
MARKET CAP
53.45M
P/E (TTM)
-0.9258
1D
5D
1M
3M
1Y
5Y
Ocuphire's APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting
Oral Administration of APX3330 Reduced Neovascularization in a Pre-Clinical Mouse Model of Laser-Induced Choroidal Neovascularization
GlobeNewswire · 1d ago
Ocuphire Pharma Starts Mid-Stage APX3330 Study In Diabetic Retinopathy Patients
Benzinga · 04/08 14:43
Ocuphire Pharma (OCUP) Gets a Buy Rating from JonesTrading
In a report released today, Prakhar Agrawal from JonesTrading initiated coverage with a Buy rating on Ocuphire Pharma (OCUP) and a price target of $20.00.
SmarterAnalyst · 04/08 13:45
Ocuphire initiates mid-stage trial of APX3330 in diabetic retinopathy
Ocuphire Pharma (OCUP) announces that it has screened the first patient in ZETA-1, a Phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy ((NPDR)) and mild proliferative diabetic retinopathy
Seekingalpha · 04/08 12:40
Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 In Diabetic Retinopathy
Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that it has
Benzinga · 04/08 12:34
TSLA, NVTA, CHPT and NNOX among premarket gainers
Nano-X Imaging (NNOX) +68% as FDA OKs 510(k) for Single Source Nanox.ARC Digital X-Ray.Chembio Diagnostics (CEMI) +48%.NanoVibronix (NAOV) +24%.Leaf Group Ltd. (LEAF) +19% on being acquired by Graham Holdings for $8.50 per
Seekingalpha · 04/05 12:24
DJ Ocuphire Pharma Price Target Announced at $25.00/Share by Alliance Global Partners
Dow Jones · 04/05 11:25
DJ Ocuphire Pharma Initiated at Buy by Alliance Global Partners
Dow Jones · 04/05 11:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCUP. Analyze the recent business situations of Ocuphire Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCUP stock price target is 23.50 with a high estimate of 29.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 25
Institutional Holdings: 2.21M
% Owned: 20.23%
Shares Outstanding: 10.93M
TypeInstitutionsShares
Increased
3
16.55K
New
3
2.12M
Decreased
5
4.65K
Sold Out
2
12.47K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.09%
Pharmaceuticals & Medical Research
+0.22%
Key Executives
Chairman/Director
Cam Gallagher
President/Chief Executive Officer/Vice Chairman/Treasurer/Director
Mina Sooch
Chief Accounting Officer/Vice President - Finance
Amy Rabourn
Director
Gil Price
Lead Director/Independent Director
Sean Ainsworth
Director
Susan Benton
Director
James Manuso
Director
Alan Meyer
Independent Director
Richard Rodgers
No Data
About OCUP
Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of eye disorders. Its pipeline includes two small-molecule product candidates targeting front and back of the eye indications. The Company’s lead product candidate, Nyxol Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. Nyxol is being developed for several indications, including dim light or night vision disturbances (NVD), reversal pharmacologically-induced mydriasis (RM), and presbyopia. Its second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME).

Webull offers kinds of Ocuphire Pharma Inc stock information, including NASDAQ:OCUP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCUP stock methods without spending real money on the virtual paper trading platform.